Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,005,000.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 15,000 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total value of $1,005,000.00. Following the completion of the transaction, the chief executive officer now directly owns 242,054 shares in the company, valued at approximately $16,217,618. This represents a 5.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00.
• On Friday, September 27th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00.

Janux Therapeutics Trading Down 0.8 %

Shares of NASDAQ JANX opened at $66.30 on Friday. The company has a market cap of $3.48 billion, a price-to-earnings ratio of -56.67 and a beta of 3.29. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $71.71. The stock has a 50-day moving average price of $50.21 and a two-hundred day moving average price of $45.96.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The company’s revenue for the quarter was down 82.6% on a year-over-year basis. On average, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of JANX. Janus Henderson Group PLC grew its position in Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after acquiring an additional 721,563 shares during the last quarter. Logos Global Management LP boosted its stake in shares of Janux Therapeutics by 400.0% during the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after purchasing an additional 600,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Janux Therapeutics by 38.6% during the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after purchasing an additional 378,477 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of Janux Therapeutics by 190.2% in the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after buying an additional 259,445 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after buying an additional 156,675 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. UBS Group started coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target for the company. HC Wainwright lifted their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research report on Thursday, November 7th. Scotiabank raised their price target on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Finally, Stifel Nicolaus upped their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $79.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.